Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice.

[1]  David J Mooney,et al.  Alginate type and RGD density control myoblast phenotype. , 2002, Journal of biomedical materials research.

[2]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[3]  D. Mooney,et al.  Hydrogels for tissue engineering. , 2001, Chemical reviews.

[4]  J L Cleland,et al.  Development of poly-(D,L-lactide--coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[5]  J. J. Piek,et al.  Controlling collateral development: the difficult task of mimicking mother nature. , 2001, Cardiovascular research.

[6]  S. Epstein,et al.  Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. , 2001, Cardiovascular research.

[7]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[8]  A. Blake.  Tuck in, and enjoy! , 2000, Nature.

[9]  David J. Mooney,et al.  Controlled growth factor release from synthetic extracellular matrices , 2000, Nature.

[10]  Hyun Chul Lee,et al.  Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2000, Nature.

[11]  D. Mooney,et al.  Growth Factor Delivery from Tissue Engineering Matrices: Inducing Angiogenesis to Enhance Transplanted Cell Engraftment , 2000 .

[12]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[13]  J. Pearlman,et al.  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.

[14]  A. Goddard,et al.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. , 1999, Cytokine.

[15]  A. Mikos,et al.  Growing new organs. , 1999, Scientific American.

[16]  D. Mooney,et al.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. , 1999, The American journal of pathology.

[17]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  B. V. von Specht,et al.  Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.

[19]  A. Solomon,et al.  Management of Chronic Stable Angina: Medical Therapy, Percutaneous Transluminal Coronary Angioplasty, and Coronary Artery Bypass Graft Surgery: Lessons from the Randomized Trials , 1998, Annals of Internal Medicine.

[20]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[21]  J. Folkman,et al.  Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.

[22]  S. Epstein,et al.  Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. , 1996, Circulation.

[23]  D. Pettit,et al.  Biodegradable polymers for protein and peptide drug delivery. , 1995, Bioconjugate chemistry.

[24]  J. Isner,et al.  Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. , 1995, Journal of vascular surgery.

[25]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[26]  M. Eldar,et al.  Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. , 1993, Journal of the American College of Cardiology.

[27]  Gary M Williams,et al.  The Histopathology of Kidney Changes in Rats and Monkeys Following Intravenous Administration of Massive Doses of FCE 26184, Human Basic Fibroblast Growth Factor , 1993, Toxicologic pathology.

[28]  A. Sniderman,et al.  Enhanced Revascularization of the Ischemic Limb by Angiogenic Therapy , 1993, Circulation.

[29]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Brughera,et al.  Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). , 1992, Toxicology letters.

[31]  T. Riss,et al.  Calcium alginate beads as a slow‐release system for delivering angiogenic molecules In Vivo and In Vitro , 1992, Journal of cellular physiology.

[32]  R. Roncucci,et al.  Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor , 1991, Annals of the New York Academy of Sciences.

[33]  R Langer,et al.  Controlled and modulated release of basic fibroblast growth factor. , 1991, Biomaterials.

[34]  D J Mooney,et al.  Release from alginate enhances the biological activity of vascular endothelial growth factor. , 1998, Journal of biomaterials science. Polymer edition.

[35]  B. Zetter,et al.  Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. , 1996, Growth factors.

[36]  J. Vacanti,et al.  Tissue engineering : Frontiers in biotechnology , 1993 .

[37]  J. Folkman,et al.  The fate of intravenously administered bFGF and the effect of heparin. , 1989, Growth factors.

[38]  M. Klagsbrun.  The fibroblast growth factor family: structural and biological properties. , 1989, Progress in growth factor research.